Personalized medicine prompts push to redesign clinical trials

Article Abstract:

The US Food and Drug Administration (FDA) released its guidelines for personalized medicine in March 2005 to highlight individual differences in drug response and to detect successful targeted therapies faster. The guidelines recommend unbiased testing, such as blood-based proteomics assays, to understand the human response to the drug in a particular profile.

United States. Food and Drug Administration

---

Iressa's fall from grace points to need for better clinical trials

Article Abstract:

The cancer drug Iressa is showing worrying signs that it may not live up to its promise as the clinical trials results released in December 2004 showed the drug does not prolong survival in patients with non-small lung cancer. This will underscore the need for clinical trials designed specifically to test targeted therapies.

Evaluation, Drug therapy, Lung cancer, Non-small cell, Non-small cell lung cancer, Iressa (Medication)

---

Aggressive drug marketing tactics trigger backlash

Article Abstract:

This article criticizes the marketing tactics used by companies to sell their drugs. Sales representatives of various companies hype new drugs when older, cheaper medicines are available for the same ailment.

Marketing procedures, Pharmaceutical preparations, Pharmaceutical industry, Marketing, Company marketing practices

Similar abstracts:

• Abstracts: Contradicted and initially stronger effects in highly cited clinical research. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes
• Abstracts: Managing lipid levels in diabetes beneficial but requires clinical judgment
• Abstracts: Mysterious `Morgellons disease' prompts US investigation. From TB tests, just a 'yes or no' answer, please. Bugs gain vital ground in their battle against drugs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.